Erectile Dysfunction Clinical Trial
— Shock-EDOfficial title:
The Effectiveness of Low Energy Shockwave Therapy for Improving Erectile Dysfunction in Men: a Double Blind Randomized Controlled Trial
Verified date | August 2020 |
Source | Centre Hospitalier Universitaire de Nimes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to evaluate the change from baseline in the erectile function domain of the International Index of Erectile Function (IIEF-EF) scores in patients receiving 4 weekly treatments of shockwave therapy versus those receiving a sham treatment. The change will be evaluated at 3 months after the end of a sequence of 4 weekly treatments.
Status | Completed |
Enrollment | 154 |
Est. completion date | June 22, 2020 |
Est. primary completion date | February 21, 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 79 Years |
Eligibility |
Inclusion Criteria: - The patient has been correctly informed about the study. - The patient must have given his informed and signed consent. - The patient must be insured or beneficiary of a health insurance plan. - The patient is a man between 18 and 80 years of age. (=18 years and < 80 years) - The patient has been in a stable sexual relationship for over 3 months - The patient is consulting for erectile dysfunction lasting for over 6 months - IIEF-EF6 score between 6 and 25 - Patients have at least a natural tumescence during sexual stimulation (EHS score = 1) - Pre-inclusion: Patient is willing to have 4 weeks of PDE5i treatment at the beginning of the trial, and then stop all treatment for an additional month. - Pre-inclusion: The patient agrees to try to engage at least 3 sexual intercourses per month during this period - Inclusion: Patient has completed 4 weeks of PDE5i treatment, and then stopped all treatment for an additional month. - Patient is available for a follow up of 19 months (at time of pre-inclusion and then 17 months at time of inclusion) Exclusion Criteria: - The patient is participating in another interventional study - Within the past three months, the patient has participated in another interventional study - The patient is in an exclusion period determined by a previous study - The patient is under judicial protection - The patient is an adult under guardianship - The patient refuses to sign the consent - It is impossible to correctly inform the patient - Complete anerection - History of pelvic cancer surgery (radical prostatectomy, cystectomy, abdominoperineal resection of the rectum) - Untreated testosterone deficiency - Neurological disease affecting the central nervous system - Untreated psychiatric disease, or psychiatric disease that may compromise study participation - Anatomical malformation of the penis considered by the investigator as being able to prevent vaginal penetration - Chronic haematological pathology associated with risk of haemorrhage - Oral or injectable antiandrogen treatment - The patient is taking blood thinners AND/OR has an International Normalized Ratio >3 - Known allergy to treatments used in the study (e.g. Cialis, gel) Exclusion criteria: The patient has contraindications for Cialis as mentioned in the SPC, re-given here : - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the SPC. - In clinical studies, tadalafil was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and tadalafil on the nitric oxide/cGMP pathway. Therefore, administration of CIALIS to patients who are using any form of organic nitrate is contraindicated. (see section 4.5 of the SPC). - CIALIS, must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease. - The following groups of patients with cardiovascular disease were not included in clinical trials and the use of tadalafil is therefore contraindicated: - patients with myocardial infarction within the last 90 days, - patients with unstable angina or angina occurring during sexual intercourse, - patients with New York Heart Association Class 2 or greater heart failure in the last 6 months, - patients with uncontrolled arrhythmias, hypotension (< 90/50 mm Hg), or uncontrolled - uncontrolled hypertension, - patients with a stroke within the last 6 months. - CIALIS is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4 of the SPC). |
Country | Name | City | State |
---|---|---|---|
France | CHU de Bordeax - Hôpital Pellegrin | Bordeaux | |
France | APHP - Hôpital Raymond-Poincaré | Garches | |
France | Clinique Beau Soleil | Montpellier | |
France | CHRU de Nîmes - Hôpital Universitaire Carémeau | Nîmes Cedex 09 | |
France | CHU de Lyon - Centre Hospitalier Lyon Sud | Pierre Benite |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in IIEF-EF score | Month 0 versus Month 4 | ||
Secondary | % patients with improvement | The presence/absence of improvement in erectile function as compared to baseline. Improvement in erectile function is defined as a >2 point increase in the IIEF-EF score from baseline for mild erectile dysfunction, >5 points for moderate erectile dysfunction and >7 points for severe erectile dysfunction(Rosen et al. 2011) | Month 0 versus Month 4 | |
Secondary | % patients with improvement | The presence/absence of improvement in erectile function as compared to baseline. Improvement in erectile function is defined as a >2 point increase in the IIEF-EF score from baseline for mild erectile dysfunction, >5 points for moderate erectile dysfunction and >7 points for severe erectile dysfunction(Rosen et al. 2011) | Month -2 versus Month -1 | |
Secondary | % patients with improvement | The presence/absence of improvement in erectile function as compared to baseline. Improvement in erectile function is defined as a >2 point increase in the IIEF-EF score from baseline for mild erectile dysfunction, >5 points for moderate erectile dysfunction and >7 points for severe erectile dysfunction(Rosen et al. 2011) | Month 0 versus Month 2 | |
Secondary | % patients with improvement | The presence/absence of improvement in erectile function as compared to baseline. Improvement in erectile function is defined as a >2 point increase in the IIEF-EF score from baseline for mild erectile dysfunction, >5 points for moderate erectile dysfunction and >7 points for severe erectile dysfunction(Rosen et al. 2011) | Month 0 versus Month 8 | |
Secondary | % patients with improvement | The presence/absence of improvement in erectile function as compared to baseline. Improvement in erectile function is defined as a >2 point increase in the IIEF-EF score from baseline for mild erectile dysfunction, >5 points for moderate erectile dysfunction and >7 points for severe erectile dysfunction(Rosen et al. 2011) | Month 4 versus Month 8 | |
Secondary | Change in IIEF-EF score | Change between month -2 and month -1 | ||
Secondary | Change in IIEF-EF score from baseline | Change between month 0 and month 2 | ||
Secondary | Change in IIEF-EF score from baseline | Change between month 0 and month 8 | ||
Secondary | Change in IIEF-EF score from baseline | Change between month 4 and month 8 | ||
Secondary | % patients answering "yes" to the SEP2 | Month 0 versus month 4 | ||
Secondary | % patients answering "yes" to the SEP2 | Month -2 versus month -1 | ||
Secondary | % patients answering "yes" to the SEP2 | Month 0 versus month 2 | ||
Secondary | % patients answering "yes" to the SEP2 | Month 0 versus month 8 | ||
Secondary | % patients answering "yes" to the SEP2 | Month 0 versus month 6 | ||
Secondary | % patients answering "yes" to the SEP2 | Month 0 versus month 11 | ||
Secondary | % patients answering "yes" to the SEP2 | Month 0 versus month 14 | ||
Secondary | % patients answering "yes" to the SEP2 | Month 0 versus month 17 | ||
Secondary | % patients answering "yes" to the SEP3 | Month 0 versus month 4 | ||
Secondary | % patients answering "yes" to the SEP3 | Month -2 versus month -1 | ||
Secondary | % patients answering "yes" to the SEP3 | Month 0 versus month 2 | ||
Secondary | % patients answering "yes" to the SEP3 | Month 0 versus month 8 | ||
Secondary | % patients answering "yes" to the SEP3 | Month 0 versus month 6 | ||
Secondary | % patients answering "yes" to the SEP3 | Month 0 versus month 11 | ||
Secondary | % patients answering "yes" to the SEP3 | Month 0 versus month 14 | ||
Secondary | % patients answering "yes" to the SEP3 | Month 0 versus month 17 | ||
Secondary | % patients answering "yes" to the GAQ | Month 0 versus month 4 | ||
Secondary | % patients answering "yes" to the GAQ | Month -2 versus month -1 | ||
Secondary | % patients answering "yes" to the GAQ | Month 0 versus month 2 | ||
Secondary | % patients answering "yes" to the GAQ | Month 0 versus month 8 | ||
Secondary | % patients answering "yes" to the GAQ | Month 0 versus month 6 | ||
Secondary | % patients answering "yes" to the GAQ | Month 0 versus month 11 | ||
Secondary | % patients answering "yes" to the GAQ | Month 0 versus month 14 | ||
Secondary | % patients answering "yes" to the GAQ | Month 0 versus month 17 | ||
Secondary | Change in EHS | Month 0 versus month 4 | ||
Secondary | Change in EHS | Month -2 versus month -1 | ||
Secondary | Change in EHS | Month 0 versus month 2 | ||
Secondary | Change in EHS | Month 0 versus month 8 | ||
Secondary | Change in EHS | Month 0 versus month 6 | ||
Secondary | Change in EHS | Month 0 versus month 11 | ||
Secondary | Change in EHS | Month 0 versus month 14 | ||
Secondary | Change in EHS | Month 0 versus month 17 | ||
Secondary | Change in IIEF score (including subscores) | Month 0 versus month 4 | ||
Secondary | Change in IIEF score (including subscores) | Month -2 versus month -1 | ||
Secondary | Change in IIEF score (including subscores) | Month 0 versus month 2 | ||
Secondary | Change in IIEF score (including subscores) | Month 0 versus month 8 | ||
Secondary | Change in IIEF score (including subscores) | Month 0 versus month 6 | ||
Secondary | Change in IIEF score (including subscores) | Month 0 versus month 11 | ||
Secondary | Change in IIEF score (including subscores) | Month 0 versus month 14 | ||
Secondary | Change in IIEF score (including subscores) | Month 0 versus month 17 | ||
Secondary | Visual analog scale for pain during treatment | Immediately after treatment session. | Week 1 | |
Secondary | Visual analog scale for pain during treatment | Immediately after treatment session. | Week 2 | |
Secondary | Visual analog scale for pain during treatment | Immediately after treatment session. | Week 3 | |
Secondary | Visual analog scale for pain during treatment | Immediately after treatment session. | Week 4 | |
Secondary | Visual analog scale for pain during treatment | Immediately after treatment session. | Month 5, week 1 | |
Secondary | Visual analog scale for pain during treatment | Immediately after treatment session. | Month 5, week 2 | |
Secondary | Visual analog scale for pain during treatment | Immediately after treatment session. | Month 5, week 3 | |
Secondary | Visual analog scale for pain during treatment | Immediately after treatment session. | Month 5, week 4 | |
Secondary | The number of patients with other complications | Any other complications that might occur throughout the study (very few are listed in the literature). | Month 17 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 |